What is the group’s experience on Oral Iron + continuing ESAs while TSAT < 20%. Definitely not ideal, still I would like to know. Or traditional IV formulations like Iron Sucrose? #NephJC

Check the insightful #NephJC summary by Jeyakumar Meyyappan

Hey all, This is Akshaya, junior Nephrologist from India, #NephJC intern and aggressive HIF-PHI prescriber !! Got late, despite the multiple reminders ⏰ on my phone !! Apologies!

✨It's that time of the year again, to nominate the most deserving people in our community for #NephJCKidneys award 👇Here's a reminder of previous winners 📌You can nominate worthy individuals/ initiatives by using the hashtag or by using the form www.nephjc.com/news/...#NephJCKidneys #NephJC

Here is the VA for the INFINITI study of SGLT2i in transplant patients by @glomerican.bsky.social #NephSky #Flozins #Flozination www.nephjc.com/news/2026/2/8/infiniti-the-visual-abstract

T -15min 👉Before we start, a few reminders! Are you new to #NephJC? Not sure what to do or how this works? Here is a quick rundown, an infographic made by Sinead Stoneman#NephJC?

⏰30 min before the #NephJC chat There has been limited research on SGLT2i in renal transplant recipients till date, and this is the compilation of currently available data. #NephJC Are you pumped to know how and how well #Flozins work in transplanted patients? Let's deep dive in a few minutes!

⏰2 hours until #NephJC chat SGLT2i has transformed the world of nephrology, with sustained effects on multiple hard end-points. Do their benefits transcend to transplant patients too? Let’s discuss #flozination in Transplant recipients today, 9PM EST in the #NephJC chat. 1/2

Hey #NephSky 2/10/26 at 9 pm EST we'll discuss #Flozinating into the Future & Beyond... SGLT2i in kidney transplant recipients. What's the latest evidence of risk/benefit? Do #Flozins act mechanistically the same in de-innervated kidneys? Come chat. www.nephjc.com/news/inifinti-flozins-transplant

Potassium sits at the center of physician anxiety 😟 Tonight, we ask a provocative question with POTCAST 👉 Are we really targeting the “correct” potassium range? #NephJC

Oh, the weather outside is frightful 🥶🥶 But #NephJC is so delightful, and since you've no place to go #NephSky... Come discuss POTCAST: potassium goals and cardiac arrhythmias 1/27/26 at 9pm EST on #Bluesky Summary by @shelliefravel.bsky.social @salinesolut.bsky.social www.nephjc.com/news/potcast

6/10 Give me something clever to say 🤓 @nephromommy-akshu.bsky.social bsky.app/profile/neph...

🎨Beautiful visual abstract by Dr Akshaya Akshaya Jayachandran #NephJC

Hey #NephJC friends! Sayali here, from Mumbai! Perplexed and vexed by this disease. Waiting for a cure, & more importantly, waiting for the cure to be shipped to India! Good job on the abstract @nephromommy-akshu.bsky.social & summary @drsaivani.bsky.social ! 👍🏻

T0b The pathophysiology of C3GN & IC-MPGN is thought to be caused by: Genetic mutations or Acquired defect of complement proteins or Auto-antibodies against complement factors and/or regulating proteins. #NephJC

⏰2 hours until #NephJC chat Join us today to learn more about the recently released VALIANT study, which investigates the use of Pegcetacoplan in C3 glomerulonephropathy and immune complex mediated glomerulonephritis

We will be discussing C3G today - so review the disease and the journey so far with Prof Carla Nester: youtu.be/Fo6J__RgWA0?... From our #NephGR a few months ago Excellent crisp overview of the science!

Check out the VA for VALIANT from @nephromommy-akshu.bsky.social #NephJC www.nephjc.com/news/2026/1/11/valiant-the-visual-abstract

🧬 C3G APPEAR-C3G or VALIANT? 📉 Proteinuria vs placebo: 🔹 Iptacopan: 35% 🔹 Pegcetacoplan: 67% 🎯 Blocking factor B 🆚 🚫C3 Where would you place your bet today? #nephsky #Medsky @thelancet.com @nejm.org 🦋 join us today on #nephjc

Join us for the last #NephJC of 2025, 12/16/25 at 9pm EST!🥳 How soon should we withhold dialysis in AKI? We're discussing the LIBERATE-D trial #NephSky This one might just change your mind 🧠🧠 Blog by @msocomd.bsky.social and @sejalplakhani.bsky.social www.nephjc.com/news/liberated-aki

T3d Benefits may vary, and results in the general population on CV risk and mortality are still controversial. Overall, the results of recent studies have been mixed results. Different study populations, end points and dosing may account for the lack of clarity. #NephJC

Hey this is Akshaya, junior faculty from CMC Vellore, India. Currently joining in from Taiwan 🇹🇼 - here for the APCN ! 🐟 Honestly, most of my CKD patients are poor and I’ve been guilty of stopping some of their randomly prescribed fish oil because it costed them a whale! #NephJC

Holy Mackerel! 🐟 🦜Ahoy matey! Could fish oil unlock the mysteries of increased CV mortality in ESRD? 🏴‍☠️ #NephJC Join us for a lively trawling trip 12/2/25 🛥️at 9pm EST Check out the PISCES VA by @brianrifkin.bsky.social www.nephjc.com/news/piscesva

A result this shiny usually means you check for scales! 🎣 Do read and enjoy our #NephJC summary/critical appraisal of the 🐟PISCES 🐟 Study (Fish Oil in Dialysis) www.nephjc.com/news/pisces-... @nephjc.bsky.social

⏰ 2 hours until chat tonight #NephJC editorial team debated for a long time...not whether to discuss @kdigo.org IgAN guidelines, but whether to do it after #Kidneywk...Have we said it well: IgAN guidelines: fresh out of press, already aging gracefully? 👀See it for yourself

TOM of this month goes to ACHIEVE trial (n=2,538), which showed that spironolactone 25 mg daily did not reduce CV events or mortality in dialysis patients, and increased risk of severe hyperkalemia #VA by @nephromommy-akshu.bsky.social. See the latest #ISNTrialWatch summary for details.

Highlights from my talk yesterday on Alport syndrome spectrum of disorders. (since no one posted it, I'll have to do it myself) Variants in type IV collagen cause a wide spectrum of disease. #KidneyWk 🧵

Zigakibart was well tolerated and cut #proteinuria by 60% while stabilizing #kidney function in #IgAN patients over 100 weeks. #nephrology #nephsky #iganephropathy docwirenews.com/post/zigakib...

The 2025 @kdigo.org IgAN guideline quietly redraws the map: new drugs, new thresholds, and a sense that the era of “supportive care only” is finally over #Nephsky #Medsky ✍️Summary by @thekidneywhisperer.bsky.social and @glomerican.bsky.social www.nephjc.com/news/igan-kd...

Wonderful ! 😇 A patient’s perspective on IgA Nephropathy ! #NephJC #Nephsky #MedSky

⏩ Next #NephJC is on IgA nephropathy @kdigo.org guideline 🎨 Nice visual summary by @roxnonna23.bsky.social www.nephjc.com/news/2025/10...

Hey this is Akshaya, nephrologist from India! We’ve traditionally been restricting protein to our CKD patients until they go on to require dialysis ! A lot of our practices are changing nowadays though. Would love to get some good-y food-y insights from this chat ! #NephJC

Check at the VA for our discussion of protein diet strategies by @msocomd.bsky.social. Is restricting protein in CKD and pushing protein in ESRD #TWDFNR? www.nephjc.com/news/2025/10...

Up next! CKD & Protein: Is Your Diet a Solution or a Silent Stressor? 🥩🔍 On October 14, we're discussing protein diets and outcomes in CKD/ESRD which still remains an enigma. ☀️📚 #NephJC pubmed.ncbi.nlm.nih.gov/40876553/ #Skytorial by @nephromommy-akshu.bsky.social Akshaya's signing off 👋

10/10 Final #NephJC thoughts 🤔💭 While the study was a success, it is still a harsh reality that there exist many barriers to even getting a transplant. Much work is needed to safely simplify the procedure and make being IS - free a reliable reality for all kidney transplant patients! #NephJC

9/10 I want more info: 👓📖 Please go through the insightful summary by Akshaya Jayachandran @nephromommy-akshu.bsky.social and Natalia Nombera @roxnonna23.bsky.social 🔖📖 🎨Beautiful visual abstract by Bogdan @thekidneywhisperer.bsky.social #NephJC www.nephjc.com/news/chimera...

8/10 #NephJC Quote of the fortnight from @brianrifkin.bsky.social 💬 Immune tolerance is nice, but unpredictable and requires constant vigilance to prevent rejection. Would modifying graft kidneys to make them less antigenic be a better bet? #NdphJC

7/10 Chat consensus? 🎬 Although the study shows that the MDR-101 regimen induces chimerism and functional immune tolerance in HLA-matched living donor KTRs leading to complete IS elimination, it is far from being widely applicable. It’s too costly and works only in highly HLA matched KTRs. #NephJC

6/10 Give me something clever to say 🤓 Here’s what caught my attention! @kidneyboy.bsky.social comparing life on dialysis vs pig transplant 🐖+ IS vs Live donor transplant 🫘and IS free! Definitely stuff worthy of a sci-fi movie! 👽

5/10 A figure paints 🖼️ 1000 words! KDQOL-SF36 data showed huge improvement in Burden of Kidney Disease and Mental Health Composite Scores at two and three years when patients were off IS. This demonstrates that even low-dose IS negatively impacts patient quality of life. 🙆💊 #NephJC

4/10 One post results 📊 75% (15/20) of KTRs achieved functional immune tolerance (IS-free for two years) using the mixed chimerism strategy with MDR-101💉 The study showed 100% patient/graft survival and zero GVHD cases over three years, with improved quality of life. 4/20 KTRs resumed IS. #NephJC

3/10 One Post Methods 👩‍🏫 Phase 3, prospective, open-label, randomized, multicenter trial - USA/Canada. Included kidney transplant recipients (KTR) from a 2-haplotype HLA-matched, living donors. Primary outcome - functional immune tolerance - staying off all IS for at least 24 months. 💊 #NephJC

2/10 What’d I miss? Transplant immunosuppression (IS) causes significant drug toxicities, infection, cancer risks & huge costs 💸. “Functional tolerance” is a state in which the recipient’s immune system accepts the graft without additional IS. It has remained the "Holy grail" of transplant! #NephJC

1/10 Welcome to #TenPostNephJC Last #NephJC we discussed tolerance induction in HLA matched 🫘 transplants with donor Hematopoietic stem cells (MDR-101). Missed the Chimeri-chat? No worries - We’re quite “tolerant” to those who missed their IS(Informative Session)! pubmed.ncbi.nlm.nih.gov/39922283/

What great cha Excellent article Fantastic write up for the summary Great chat with good turn out This is a good week for #NephJC Thanks everyone

The conditioning regimen and bespoke cell product are highly specialized and costly. How do we translate this success to resource-limited centers? Cost & logistics make MDR-101 a first-world solution for now. #NephJC

Check out the insightful summary by Dr Akshaya Jayachandran @nephromommy-akshu.bsky.social and Dr Natalia Nombera @roxnonna23.bsky.social #NephJC

Hey I'm Akshaya Jayachandran, #NephJC intern 2025, and a young Nephrologist from CMC Vellore, India. No COIs. From an economy where IS costs remain a major reason for drug noncompliance leading to graft loss, this trial - if successfully done in higher risk transplants, would be a boon!

Be like Matt. Shoot us a dime so we can keep the #FOAMed flowing